Viking offers asymmetric upside in GLP-1 drugs with positive trial data, strong cash, and buyout potential despite biotech ...
Zacks Investment Research on MSN
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
Viking Therapeutics, Inc. (VKTX) closed at $27.88 in the latest trading session, marking a +1.86% move from the prior day. This move outpaced the S&P 500's daily gain of 0.06%. Meanwhile, the Dow ...
At the end of Q2, the biotech has a cash balance of $808 million and burned $95 million in the 1H of the year. Viking ...
Weight loss drugs have represented an enormous growth area for biotech and pharma companies over the past couple of years.
From a technical perspective, Viking Therapeutics shares are attempting to break out of their recent consolidation pattern. While the stock posted a 2.01% gain over the past month, it has ...
Zacks.com on MSN
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $24.97, denoting a -4.88% move from the preceding trading day.
Zacks.com on MSN
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $25.09, indicating a -5.78% shift from the previous trading day.
With J.J. McCarthy returning to health, the Vikings are considered a candidate to make a QB trade and move Carson Wentz at the NFL deadline.
A to Z Sports on MSN
The Minnesota Vikings have an offensive line problem once again with it being both their fault and one they couldn't prevent
Once again, the Minnesota Vikings have an issue on the offensive line. We've been down this road before, especially since ...
A Minnesota Vikings trade proposal has the team trade for Kansas City Chiefs running back, Kareem Hunt, to bolster the unit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback